3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
202
Leukemia, Lymphocytic, Chronic, B-Cell
54
Recurrence
37
Neoplasms, Plasma Cell
30
Lymphoma, Mantle-Cell
30
Lymphoma
30
Lymphoma, Follicular
29
Lymphoma, Large B-Cell, Diffuse
27
Leukemia
23
Leukemia, Myeloid, Acute
22
Lymphoma, Non-Hodgkin
21
Lymphoma, B-Cell, Marginal Zone
15
Myelodysplastic Syndromes
13
Hodgkin Disease
12
Waldenstrom Macroglobulinemia
8
Prostatic Neoplasms
8
Lymphoma, T-Cell
8
Smoldering Multiple Myeloma
7
Immunoglobulin Light-chain Amyloidosis
7
Neoplasms
6
Melanoma
6
Lymphoma, B-Cell
6
Hematologic Diseases
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, T-Cell, Cutaneous
5
Lymphoma, Large-Cell, Anaplastic
5
Leukemia, Myelomonocytic, Chronic
5
Hematologic Neoplasms
5
Amyloidosis
5
Sezary Syndrome
4
Interventions
blinatumomab
5
dacetuzumab
4
Rituximab
3
venetoclax
1
tetulomab tetraxetan lu-177
1
ponatinib
1
pembrolizumab
1
ibrutinib
1
ficlatuzumab
1
durvalumab
1
denileukin diftitox
1
Tinzaparin
1
Standard of Care
1
Lutetium
1
Lenalidomide
1
Gemcitabine
1
Everolimus
1
Erlotinib Hydrochloride
1
Cyclophosphamide
1
Brentuximab Vedotin
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphatic Diseases
×
Lenalidomide
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts